• Read our press releases

    Some of our recent press releases are highlighted below. To view all of our past press releases, or to view them in Swedish, please visit our Global or Swedish Newsrooms using the link buttons at the bottom of this page.

    December 14, 2017 – Olink Proteomics announces the availability of the most comprehensive, high-multiplex protein biomarker panel for mouse studies

    Olink Proteomics today announced the launch of Olink® MOUSE EXPLORATORY, offering 92 high-quality assays to measure mouse proteins. The panel is based on the same, well-established Proximity Extension Assay (PEA) technology behind Olink’s portfolio of high-multiplex panels for human protein biomarker discovery, and has been developed to the same high standards of validation and quality control.
    View the full press release >>

    February 16, 2017 – Olink Proteomics announces the availability of three additional biomarker panels focused on key biological processes with broad clinical relevance

    Olink Proteomics today announced the launch of three new precision proteomics panels, further expanding its rapidly growing library of high quality human protein biomarker assays to almost 1000. The focus areas for these three new panels are Cardiometabolic, Cell Regulation and Development.
    View the full press release >>

    November 29, 2016 – Olink Proteomics announces the availability of three new biomarker panels to further explore the complexities of the human proteome

    Olink Proteomics today announced the launch of three new precision proteomics panels, significantly expanding its library of high quality human protein biomarker assays, from 460 to over 700. This series of new panels is designed to enable scientists to extend their discovery capabilities for studying the plasma proteome by casting a broader net, thereby maximizing their chances of identifying clinically relevant protein signatures.
    View the full press release >>

    September 21, 2016 – Olink Proteomics announces the availability of the broadest and most complete protein biomarker panel for immuno-oncology.

    Olink Proteomics today announced that Proseek®Multiplex Immuno-Onc I, the broadest protein biomarker panel targeting critical biological process related to immunotherapy, is now available for immediate delivery. Developed to meet a clearly expressed need from customers, the panel is designed to help companies, scientists and clinicians working with immunotherapy-based approaches to treat cancer.
    View the full press release >>

    May 31, 2016 –  Open for business in the USA: Olink Proteomics unveils a new office and analysis service laboratory in the Boston area.

    Olink Proteomics is delighted to announce the opening of new office and laboratory facilities in Watertown, Massachusetts. This heralds the establishment of the company’s first major regional organization outside of Sweden, and will support the rapidly growing business in the United States.
    View the full press release >>

    April 12, 2016 – A new company organization to meet our future ambitions

    Olink AB has gone through a formal reorganization, and as of April 1, 2016 is operating as two separate companies, each with its own distinct focus area.

    Olink Proteomics will continue to expand and develop the Proseek® Multiplex product line for targeted human protein biomarker discovery, while Olink Bioscience will focus on developing and commercializing the many additional technologies held within Olink’s extensive and growing, diverse IP portfolio.
    View the full Press Release >>

     

    January 27, 2016 – Olink introduces a new precision proteomics solution for neurology

    Olink today launched Proseek® Multiplex Neurology I, a new human protein biomarker panel that targets research into neurobiology and neurological diseases. This latest development of the Proseek platform expands the library of unique biomarkers available to over 440 in total, and opens up Olink’s innovative precision proteomics offering into a new and exciting field.
    View the full press release >>